For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Factor VIII is a blood clotting protein which is also called anti-hemophilic factor (AHF). Factor VIII is produced in the liver and in the endothelial cells of other organs and tissues. It circulates in the bloodstream as an inactive form complexed with von Willebrand factor (vWF). In damaged blood vessels Factor VIII disassociates from vWF to become active Factor VIII. Activated Factor VIII initiates the cascade of chemical reactions to promote blood clotting at the site of vessel damage to prevent blood loss from the body. For this reason, it has been used as a blood clotting drug for patients with hemophilia to restore hemostasis. The present kit detects hFactor VIII in human serum, plasma, cell culture supernatants, and cell lysate and tissue homogenates.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target||Factor VIII|
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.